Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study

BACKGROUND: Although bevacizumab in combination with afatinib or erlotinib is an effective and safe first-line therapy for advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), there are very few clinical data comparing afatinib and erlotinib combined with beva...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Suey-Haur, Lin, Yu-Ching, Chiu, Li-Chung, Ju, Jia-Shiuan, Tung, Pi-Hung, Huang, Allen Chung-Cheng, Li, Shih-Hong, Fang, Yueh-Fu, Chen, Chih-Hung, Kuo, Scott Chih-Hsi, Wang, Chin-Chou, Yang, Cheng-Ta, Hsu, Ping-Chih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310205/
https://www.ncbi.nlm.nih.gov/pubmed/35898964
http://dx.doi.org/10.1177/17588359221113278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310205/
https://www.ncbi.nlm.nih.gov/pubmed/35898964
http://dx.doi.org/10.1177/17588359221113278

Ejemplares similares